Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Short Stature
Conditions
Idiopathic Short Stature
Trial Timeline
Nov 1, 2010 → Sep 1, 2016
NCT ID
NCT01248416About Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone is a phase 3 stage product being developed by AstraZeneca for Idiopathic Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT01248416. Target conditions include Idiopathic Short Stature.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01248416 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Short Stature